WO2003024446A1 - Oxidation stress inhibitor and method of measuring oxidation stress - Google Patents

Oxidation stress inhibitor and method of measuring oxidation stress Download PDF

Info

Publication number
WO2003024446A1
WO2003024446A1 PCT/JP2002/009087 JP0209087W WO03024446A1 WO 2003024446 A1 WO2003024446 A1 WO 2003024446A1 JP 0209087 W JP0209087 W JP 0209087W WO 03024446 A1 WO03024446 A1 WO 03024446A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxidation stress
diseases
brain
various
measuring
Prior art date
Application number
PCT/JP2002/009087
Other languages
French (fr)
Japanese (ja)
Inventor
Yorihiro Yamamoto
Chizuko Takahashi
Kazutoshi Watanabe
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Priority to JP2003528542A priority Critical patent/JPWO2003024446A1/en
Publication of WO2003024446A1 publication Critical patent/WO2003024446A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

It is intended to provide an oxidation stress inhibitor containing as the active ingredient a pyrazolone derivative represented by the formula (I) as defined in the description or its pharmaceutically acceptable salt; and a method of measuring oxidation stress characterized by using a monounsaturated fatty acid, ubiquinone-10 or cholesterol ester hydroperoxide in the plasma as a marker, a clinical examination method a method of evaluating a drug. The above-mentioned drug is useful as a preventive/a remedy for various oxidation stress diseases (for example, ischemic diseases and various diseases depending thereon, namely, cerebrovascular diseases such as brain infarction and brain attack, brain hypofunction and vascular dementia caused thereby, various brain diseases in association with aging such as cerebrovascular tissue lesion, various peripheral circulatory disorders based on cardiomuscular ischemia such as cardiomuscular infarction and heart failure, liver failure, and diabetes). The above-mentioned method of measuring oxidation stress makes it possible to accurately and quantitatively measure oxidation stress, which makes it applicable to clinical examinations and evaluation of drugs.
PCT/JP2002/009087 2001-09-11 2002-09-06 Oxidation stress inhibitor and method of measuring oxidation stress WO2003024446A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003528542A JPWO2003024446A1 (en) 2001-09-11 2002-09-06 Oxidative stress inhibitor and method for measuring oxidative stress

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-275466 2001-09-11
JP2001275466 2001-09-11
JP2001-275467 2001-09-11
JP2001275467 2001-09-11

Publications (1)

Publication Number Publication Date
WO2003024446A1 true WO2003024446A1 (en) 2003-03-27

Family

ID=26622015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009087 WO2003024446A1 (en) 2001-09-11 2002-09-06 Oxidation stress inhibitor and method of measuring oxidation stress

Country Status (2)

Country Link
JP (1) JPWO2003024446A1 (en)
WO (1) WO2003024446A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080583A1 (en) * 2002-03-27 2003-10-02 Mitsubishi Pharma Corporation Medicine for prevention and/or therapy of cardiomyopathy
JP2004307364A (en) * 2003-04-03 2004-11-04 Yuutoku Yakuhin Kogyo Kk Transdermal patch
WO2005046680A1 (en) * 2003-11-12 2005-05-26 Lead Chemical Co., Ltd. Percutaneous absorption type cerebral protective agent
WO2005054205A1 (en) * 2003-12-05 2005-06-16 Tokai University Educational System Protein modifier production inhibitor
WO2005122033A1 (en) * 2004-06-08 2005-12-22 Intellectual Property Bank Corp. Medical total information apparatus and medical total information system
JP2006119036A (en) * 2004-10-22 2006-05-11 Fuso Pharmaceutical Industries Ltd Early diagnosis method of cardiac disease by measurement of fatty acid concentration in blood
JP2006298774A (en) * 2005-04-15 2006-11-02 Lead Chemical Co Ltd Percutaneous absorption type free radical-inhibiting preparation
JP2007225607A (en) * 2006-01-27 2007-09-06 Prima Meat Packers Ltd Method of screening antistress agent, and method of determining effectiveness thereof
WO2010087306A1 (en) 2009-01-29 2010-08-05 株式会社林原生物化学研究所 Anti-neurodegenerative disease agent
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US8273882B2 (en) 2008-05-23 2012-09-25 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
CN107365315A (en) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 A kind of pyrazole compound, its crystal formation and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108814A (en) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd Inhibitor against formation of peroxide lipide
EP0249735A2 (en) * 1986-05-20 1987-12-23 A. Nattermann & Cie. GmbH Pharmaceutical preparations comprising as active agent 2-phenyl-1.2-benzisoselenazol-3(2H)-one, for the treatment of diseases caused by oxidative stress
JPH03215425A (en) * 1990-01-16 1991-09-20 Mitsubishi Kasei Corp Antiulcer agent
EP0633025A1 (en) * 1993-07-07 1995-01-11 Mitsubishi Chemical Corporation Pharmaceutical composition containing 3-methyl-1-phenyl-2-pyrazolin-5-one for the treatment of ophthalmological diseases
WO1999063341A2 (en) * 1998-05-29 1999-12-09 Nikken Foods Co., Ltd. Use of oxidative stress diagnostic plot as a health indicator for assessing oxidative stress and its control in humans
WO1999064424A1 (en) * 1998-06-09 1999-12-16 Takara Shuzo Co., Ltd. Therapeutic agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108814A (en) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd Inhibitor against formation of peroxide lipide
EP0249735A2 (en) * 1986-05-20 1987-12-23 A. Nattermann & Cie. GmbH Pharmaceutical preparations comprising as active agent 2-phenyl-1.2-benzisoselenazol-3(2H)-one, for the treatment of diseases caused by oxidative stress
JPH03215425A (en) * 1990-01-16 1991-09-20 Mitsubishi Kasei Corp Antiulcer agent
EP0633025A1 (en) * 1993-07-07 1995-01-11 Mitsubishi Chemical Corporation Pharmaceutical composition containing 3-methyl-1-phenyl-2-pyrazolin-5-one for the treatment of ophthalmological diseases
WO1999063341A2 (en) * 1998-05-29 1999-12-09 Nikken Foods Co., Ltd. Use of oxidative stress diagnostic plot as a health indicator for assessing oxidative stress and its control in humans
WO1999064424A1 (en) * 1998-06-09 1999-12-16 Takara Shuzo Co., Ltd. Therapeutic agents

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080583A1 (en) * 2002-03-27 2003-10-02 Mitsubishi Pharma Corporation Medicine for prevention and/or therapy of cardiomyopathy
JP2004307364A (en) * 2003-04-03 2004-11-04 Yuutoku Yakuhin Kogyo Kk Transdermal patch
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
JPWO2005046680A1 (en) * 2003-11-12 2007-06-14 リードケミカル株式会社 Transdermal brain protective agent
WO2005046680A1 (en) * 2003-11-12 2005-05-26 Lead Chemical Co., Ltd. Percutaneous absorption type cerebral protective agent
JP5131578B2 (en) * 2003-11-12 2013-01-30 リードケミカル株式会社 Transdermal brain protective agent
US8076368B2 (en) 2003-11-12 2011-12-13 Lead Chemical Co., Ltd, Percutaneous absorption type cerebral protective agent
KR101008052B1 (en) * 2003-11-12 2011-01-13 리도 케미칼 가부시키가이샤 Percutaneous absorption type cerebral protective agent
JP4837992B2 (en) * 2003-12-05 2011-12-14 学校法人東海大学 Protein modification product inhibitor
EP1693369A4 (en) * 2003-12-05 2011-06-22 Univ Tokai Educational System Protein modifier production inhibitor
WO2005054205A1 (en) * 2003-12-05 2005-06-16 Tokai University Educational System Protein modifier production inhibitor
KR101205748B1 (en) 2003-12-05 2012-11-28 토카이 유니버시티 에듀케이셔널시스템 Inhibitor of protein modification products formation
JPWO2005054205A1 (en) * 2003-12-05 2007-06-28 学校法人東海大学 Protein modification product inhibitor
EP1693369A1 (en) * 2003-12-05 2006-08-23 Tokai University Educational System Protein modifier production inhibitor
WO2005122033A1 (en) * 2004-06-08 2005-12-22 Intellectual Property Bank Corp. Medical total information apparatus and medical total information system
JPWO2005122033A1 (en) * 2004-06-08 2008-07-31 有喜 北岡 Medical integrated information device and integrated medical information system
JP4522222B2 (en) * 2004-10-22 2010-08-11 扶桑薬品工業株式会社 Early diagnosis of heart disease by measuring blood fatty acid concentration
JP2006119036A (en) * 2004-10-22 2006-05-11 Fuso Pharmaceutical Industries Ltd Early diagnosis method of cardiac disease by measurement of fatty acid concentration in blood
JP2006298774A (en) * 2005-04-15 2006-11-02 Lead Chemical Co Ltd Percutaneous absorption type free radical-inhibiting preparation
JP2007225607A (en) * 2006-01-27 2007-09-06 Prima Meat Packers Ltd Method of screening antistress agent, and method of determining effectiveness thereof
US8273882B2 (en) 2008-05-23 2012-09-25 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US8674099B2 (en) 2008-05-23 2014-03-18 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
WO2010087306A1 (en) 2009-01-29 2010-08-05 株式会社林原生物化学研究所 Anti-neurodegenerative disease agent
CN107365315A (en) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 A kind of pyrazole compound, its crystal formation and preparation method thereof

Also Published As

Publication number Publication date
JPWO2003024446A1 (en) 2004-12-24

Similar Documents

Publication Publication Date Title
WO2003024446A1 (en) Oxidation stress inhibitor and method of measuring oxidation stress
Vogel Measurement of endothelial function by brachial artery flow-mediated vasodilation
Riegger et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
Virdis et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension
Hishikawa et al. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells
Topouchian et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension
Romero et al. Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats
JP4608214B2 (en) How to use polyunsaturated ketones to treat psoriasis
Huang et al. Sterculic acid antagonizes 7-ketocholesterol-mediated inflammation and inhibits choroidal neovascularization
JP2004210797A (en) Therapeutic combination comprising amlodipin and atorvastatin
Hayoz et al. Postischemic blood flow response in hypercholesterolemic patients
Meral et al. Effects of lidocaine with and without epinephrine on plasma epinephrine and lidocaine concentrations and hemodynamic values during third molar surgery
Karatzis et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina
Galetta et al. Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects
WO2017062924A1 (en) Dosing regimens of pkc activators
MX9304503A (en) ANTI-INFLAMMATORY COMPOUNDS.
Dumont et al. Improvement of endothelial function in insulin-resistant carotid arteries treated with pravastatin
Masumoto et al. Specific attenuation of the pressure-induced contraction of rat cerebral artery by herbimycin A
Delgado Spicuzza et al. Menopausal stage differences in endothelial resistance to ischemia‐reperfusion injury
Diaz et al. Differential effects of resveratrol on the dilator responses of femoral arteries, ex vivo
US20130338203A1 (en) TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
Lu et al. I4, a new synthetic sulfonylurea compound, inhibits the action of TXA2 in vivo and in vitro on platelets and aorta vascular smooth muscle
Studinger et al. Effect of vitamin E on carotid artery elasticity and baroreflex gain in young, healthy adults
Monreal et al. Right ventricular remodeling in restrictive ventricular septal defect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003528542

Country of ref document: JP

122 Ep: pct application non-entry in european phase